IP Verse

Pharmaceutical Composition Comprising Bisoprolol And Perindoril - EP3215130

The patent EP3215130 was granted to LES Laboratoires Servier on Jul 8, 2020. The application was originally filed on Nov 4, 2015 under application number EP15807949A. The patent is currently recorded with a legal status of "Revoked".

EP3215130

LES LABORATOIRES SERVIER
Application Number
EP15807949A
Filing Date
Nov 4, 2015
Status
Revoked
Jan 20, 2023
Grant Date
Jul 8, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KRKAApr 8, 2021HOEFER & PARTNER PATENTANWALTE MBBADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2007010501
INTERNATIONAL-SEARCH-REPORTWO2010038091
OPPOSITIONUS2004137054
OPPOSITIONWO2007010501
OPPOSITIONWO2010038091
OPPOSITIONWO2011138772

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- A. MADEJ et al., "Short-term antihypertensive therapy lowers the C-reactive protein level", Postepy Hig Med Dosw, vol. 66, (20120000), pages 78 - 84, XP055797560-
OPPOSITION- A. MADEJ et al., "The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines", International Journal of Clinical Pharmacology and Therapeutics, (20090000), vol. 47, no. 11, pages 686 - 694, XP055797549-
OPPOSITION- "Cardicor 2.5mg Film Coated Tablets", medicines.org, (20201106), URL: https://www.medicines.org.uk/emc/product/7768/smpc, XP055797566-
OPPOSITION- "Dosage Forms: Non-Parenterals", Encyclopedia of Pharmaceutical Technology, (20070000), pages 988 - 993, XP055797579-
OPPOSITION- KG ADAMYAN, "Bisoprolol and perindopril combination in post infarction left ventricle remodelling", Circulation, (20080000), vol. 118, no. 12, page P373, XP055797555-
OPPOSITION- K. H. BAUER et al., "chapter14", LEHRBUCH DER PHARMAZEUTISCHEN TECHNOLOGIE,, (20020000), pages 344 - 347, XP055797540-
OPPOSITION- P. REDDY et al., "BI-LAYER TECHNOLOGY - AN EMERGING TREND: A REVIEW", International Journal of Research and Development in Pharmacy and Life Sciences, (20130500), vol. 2, no. 3, pages 404 - 411, XP055797575-
OPPOSITION- A. ABEBE et al., "Review of bilayer tablet technology", International Journal of Pharmaceutics, vol. 461, doi:10.1016/j.ijpharm.2013.12.028, (20131224), pages 549 - 558, XP028810425
OPPOSITION- E. TELEJKO, "Perindopril arginine: benefits of a new salt of the-ACE inhibitorperindopril", Current Medical Research and Opinion, (20070000), vol. 23, no. 5, pages 953 - 960, XP008152666

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents